Precigen discovered novel PRGN-2012 AdenoVerse™ Immunotherapy designed specifically for patients suffering from recurrent respiratory papillomatosis.
The PRGN-2012 AdenoVerse™ Immunotherapy utilises advanced antigen design techniques and leverages gorilla adenovector technology to trigger targeted immune responses against cells infected with human papillomavirus type 6 (HPV 6) or HPV type 11 (HPV 11).
Gorilla adenovectors offer several significant benefits, such as the capacity for repeated administration, inability to replicate in the body, and the ability to deliver substantial genetic material payloads. In preclinical studies, PRGN-2012 has exhibited robust and highly targeted immune responses against HPV 6 and HPV 11.
Recurrent respiratory papillomatosis (RRP) is a rare and challenging disease affecting the upper and lower respiratory tracts. It is characterised by the growth of neoplastic (tumour-like) papillomas caused by infection with HPV 6 or HPV 11. Currently there is currently no cure for RRP.
Recurrence of papillomas after surgery is very common, and removal and monitoring of the disease require repeated procedures, exposing patients to anaesthetic and surgical risks and emotional stress.
US Food and Drug Administration (FDA) grants breakthrough therapy designation for the first-in-class investigational PRGN-2012 AdenoVerse immunotherapy.
